CLINICAL UTILITY OF SERUM LEVELS OF UBIQUITIN C-TERMINAL HYDROLASE AS A BIOMARKER FOR SEVERE TRAUMATIC BRAIN INJURY.

Mondello, S; Akinyi, L; Buki, A [Büki, András (Idegsebészet, ide...), szerző] Idegsebészeti Klinika (PTE / ÁOK); Robicsek, S; Gabrielli, A; Tepas, J; Papa, L; Brophy, GM; Tortella, F; Hayes, RL; Wang, KK

Angol nyelvű Tudományos Szakcikk (Folyóiratcikk)
Megjelent: NEUROSURGERY 0148-396X 1524-4040 70 (3) pp. 666-675 2012
  • SJR Scopus - Surgery: D1
Azonosítók
Szakterületek:
    BACKGROUND: Brain damage markers released in cerebrospinal fluid (CSF) and blood may provide valuable information about diagnosis and outcome predictionafter traumaticbrain injury (TBI). OBJECTIVE: This study examined concentrations of a novel brain injury biomarker Ubiquitin C-terminal Hydrolase-L1 (UCH- L1) in CSF and serum of severe TBI patients and their association with clinical characteristics and outcome. METHODS: This case-control study enrolled ninety-five severe TBI subjects (Glasgow Coma Score [GCS]5.22ng/mlpredicted death (odds ratio 4.8). CONCLUSION: Taken together, serum levels of UCH-L1 appear to have potential clinical utility in diagnosing TBI, including correlating to injury severity and survival outcome.
    Hivatkozás stílusok: IEEEACMAPAChicagoHarvardCSLMásolásNyomtatás
    2021-11-29 13:59